Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cardiol Therapeutics Inc
(TSX:
CRDL
)
2.600
+0.020 (+0.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cardiol Therapeutics Inc
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
June 17, 2024
In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II...
Via
TheNewswire.com
Exposures
Product Safety
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
June 13, 2024
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce...
Via
Newsfile
Sector Spotlight: Orphan Drug Developers With Significant Upside
June 03, 2024
Via
AB Newswire
Topics
ETFs
Exposures
Product Safety
Sector Spotlight: Orphan Drug Developers With Significant Upside
June 03, 2024
The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record...
Via
TheNewswire.com
Topics
ETFs
Exposures
Product Safety
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
May 28, 2024
Via
AB Newswire
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
February 21, 2024
This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)...
Via
Newsfile
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
February 15, 2024
This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)...
Via
Newsfile
Exposures
Product Safety
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
November 01, 2023
Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...
Via
Newsfile
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
October 10, 2023
Results Demonstrate the Active Pharmaceutical Ingredient in Cardiol's Novel CRD-38 Formulation Attenuates Harmful Fat Distribution and Key Markers of Cardiac...
Via
Newsfile
Cardiol Therapeutics On Track To Provide New Standard Of Care For Cardiovascular Diseases ($CRDL)
October 10, 2023
Via
AB Newswire
Topics
Stocks
Exposures
US Equities
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
October 02, 2023
Via
AB Newswire
Topics
Death
Exposures
Death
Product Safety
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
September 19, 2023
Recruitment Accelerating and Full Patient Enrollment Anticipated to be Completed During Q3 2024, up to Six Months Ahead of Schedule Multi-Center,...
Via
Newsfile
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America
September 28, 2022
Oakville, Ontario--(Newsfile Corp. - September 28, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...
Via
Newsfile
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
July 26, 2022
Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could...
Via
FinancialNewsMedia
Exposures
COVID-19
Product Safety
Air Pollution is a Global Heart and Lung Health Concern
July 18, 2022
Palm Beach, FL – July 18, 2022 – FinancialNewsMedia.com News Commentary – Particulate matter or particle pollution is a significant contributor to heart and lung disease. Individuals most affected by...
Via
FinancialNewsMedia
Topics
Climate Change
Emissions
Energy
Exposures
Climate
Fossil Fuels
The Healthcare Companies Fighting the World’s Biggest Killers
July 13, 2022
Palm Beach, FL – July 13, 2022 – FinancialNewsMedia.com News Commentary – Some of the most prevalent health conditions on the planet claim millions of lives every year. Companies from across the...
Via
FinancialNewsMedia
Tackling Recurring Health Conditions Offers Hope to Patients
June 21, 2022
Palm Beach, FL – June 21, 2022 – FinancialNewsMedia.com News Commentary – Being diagnosed with a health condition can often come as a shock but finding out it can recur is a double blow, particularly...
Via
FinancialNewsMedia
As Health Problems Mount Patients Welcome New Treatments
June 14, 2022
Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,...
Via
FinancialNewsMedia
Breakthroughs In Treating Killer Diseases Could Lengthen Life
June 07, 2022
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – According to the World Health Organization, top global killers include heart failure, COPD, cancers, Alzheimer’s, neonatal...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Market Movers. Today’s Top Stock Picks For New & Trending Opportunities
May 27, 2022
Market Movers. Today's Top Stock Picks For New & Trending Opportunities
From
Stockhouse Publishing
Via
AccessWire
Why Orphan Drug Designation Offers Several Benefits
May 18, 2022
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we...
Via
FinancialNewsMedia
Exposures
Product Safety
Heart Failure Treatment Offers Hope to Diabetics
May 11, 2022
Palm Beach, FL – May 11, 2022 – FinancialNewsMedia.com News Commentary – Diabetes and heart failure are closely linked. People with type 2 diabetes are two to four times more likely to develop heart...
Via
FinancialNewsMedia
Cardiol Therapeutics Reports Results of 2021 Annual General and Special Meeting
June 30, 2021
Oakville, Ontario--(Newsfile Corp. - June 30, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or...
Via
Newsfile
Exposures
COVID-19
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting on June 29th at 4:30 p.m. EDT
June 28, 2021
Oakville, Ontario--(Newsfile Corp. - June 28, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the...
Via
Newsfile
Exposures
COVID-19
Recent Surge for Intellectual Property & Patents in Psychedelic Therapies & Drug Development
June 15, 2021
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
Cardiol Therapeutics Announces First Patient Enrolled in LANCER, a Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
April 28, 2021
Oakville, Ontario--(Newsfile Corp. - April 28, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the...
Via
Newsfile
Exposures
COVID-19
Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx(TM)
April 12, 2021
Oakville, Ontario--(Newsfile Corp. - April 12, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the...
Via
Newsfile
Exposures
COVID-19
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.